BNP Paribas Financial Markets Purchases 186,524 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

BNP Paribas Financial Markets grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1,073.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 203,903 shares of the company’s stock after purchasing an additional 186,524 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.41% of Prestige Consumer Healthcare worth $15,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC increased its stake in Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after buying an additional 71,730 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Prestige Consumer Healthcare by 4.3% during the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after purchasing an additional 894 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after purchasing an additional 8,533 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Prestige Consumer Healthcare by 18.9% in the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock worth $108,000 after purchasing an additional 220 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in Prestige Consumer Healthcare by 3.4% in the 4th quarter. Nordea Investment Management AB now owns 90,693 shares of the company’s stock worth $7,066,000 after purchasing an additional 2,985 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $87.65 on Friday. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The company’s 50-day moving average is $83.18 and its 200 day moving average is $81.32. The firm has a market capitalization of $4.34 billion, a P/E ratio of 20.53, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The company had revenue of $296.52 million during the quarter, compared to analysts’ expectations of $289.36 million. During the same quarter in the previous year, the business earned $1.02 EPS. Prestige Consumer Healthcare’s revenue was up 7.0% compared to the same quarter last year. Research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Oppenheimer boosted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. StockNews.com cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Friday. Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a “hold” rating in a report on Thursday. DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Finally, Canaccord Genuity Group increased their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $93.33.

Insider Activity at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by company insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.